¼¼°èÀÇ µðÁöÅРǥÇöÇü ½ÃÀå
Digital Phenotyping
»óǰÄÚµå : 1757513
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 378 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,053,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,161,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ µðÁöÅРǥÇöÇü ½ÃÀåÀº 2030³â±îÁö 26¾ï ´Þ·¯¿¡ µµ´Þ

2024³â¿¡ 16¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ µðÁöÅРǥÇöÇü ½ÃÀåÀº 2024-2030³â¿¡ CAGR 8.6%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 26¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ ¾×Ƽºê µ¥ÀÌÅÍ ½ºÆ®¸²Àº CAGR 9.9%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 19¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÆÐ½Ãºê µ¥ÀÌÅÍ ½ºÆ®¸² ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 5.7%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 4¾ï 2,920¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 13.7%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ µðÁöÅРǥÇöÇü ½ÃÀåÀº 2024³â¿¡ 4¾ï 2,920¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀ» 13.7%·Î 2030³â±îÁö 5¾ï 7,060¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 4.3%¿Í 8.3%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 5.8%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ µðÁöÅРǥÇöÇü ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

µðÁöÅÐ Æä³ëŸÀÌÇÎÀ̶õ ¹«¾ùÀ̸ç, ¿Ö °Ç°­ ¸ð´ÏÅ͸µ¿¡¼­ ÁÖ¸ñ¹Þ´Â°¡?

µðÁöÅÐ Æä³ëŸÀÌÇÎÀº ½º¸¶Æ®Æù, ¿þ¾î·¯ºí µî °³ÀÎ¿ë µðÁöÅÐ ±â±â¿¡¼­ ½Ç½Ã°£À¸·Î µ¥ÀÌÅ͸¦ ¼öÁýÇÏ°í ºÐ¼®ÇÏ¿© °³ÀÎÀÇ Á¤½ÅÀû, ½ÅüÀû °Ç°­°ú °ü·ÃµÈ Çൿ ÆÐÅϰú »ý¸®Àû ÆÐÅÏÀ» Æò°¡ÇÏ´Â °ÍÀ» ¸»ÇÕ´Ï´Ù. µðÁöÅÐ Æä³ëŸÀÌÇÎÀº µ¿ÀÛ, ¸»Çϱâ, ŸÀÌÇÎ ÆÐÅÏ, ¼ö¸é ÁÖ±â, »çȸÀû »óÈ£ÀÛ¿ë, GPS µ¥ÀÌÅÍ µîÀÇ º¯¼ö¸¦ ¼öµ¿ÀûÀ¸·Î ¸ð´ÏÅ͸µÇÏ¿© °³ÀÎÀÇ °Ç°­ »óÅ¿¡ ´ëÇÑ ¿ªµ¿ÀûÀ̰í Áö¼ÓÀûÀÎ ÇÁ·ÎÆÄÀÏÀ» »ý¼ºÇÕ´Ï´Ù. ÀÌ·¯ÇÑ µ¥ÀÌÅͺ£À̽º Á¢±Ù ¹æ½ÄÀº ƯÈ÷ Á¤½Å°Ç°­, ½Å°æÇÐ, ¸¸¼ºÁúȯ °ü¸®¿¡¼­ ÀÌ»ó ¡Èĸ¦ Á¶±â¿¡ ¹ß°ßÇϰí, °³º°È­µÈ °³ÀÔ°ú Àå±âÀûÀÎ ÃßÀûÀ» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù.

Á¤½Å°Ç°­ À¯º´·ü Áõ°¡¿Í °³ÀÎÈ­µÈ ¿¹¹æÀû Ä¡·á¿¡ ´ëÇÑ Àü ¼¼°èÀûÀÎ °ü½ÉÀº µðÁöÅÐ Æä³ëŸÀÌÇÎÀ» µðÁöÅÐ Çコ ºÐ¾ßÀÇ È¹±âÀûÀÎ ¼Ö·ç¼ÇÀ¸·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù. µðÁöÅÐ Æä³ëŸÀÌÇÎÀº ÀÓ»óÀÇ¿¡°Ô ȯÀÚÀÇ ½ÇÁ¦ Çൿ¿¡ ´ëÇÑ ´õ ±íÀº ¸Æ¶ôÀû ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù. µðÁöÅÐ Æä³ëŸÀÌÇÎÀº µðÁöÅÐ Çൿ°ú Á¤½Å°úÀû ¶Ç´Â ½Å°æÇÐÀû °á°úÀÇ »ó°ü°ü°è¸¦ ÀÌÇØÇÏ´Â »õ·Î¿î ±æÀ» ¿­¾î Àΰ£ °Ç°­¿¡ ´ëÇÑ º¸´Ù ¹Ì¹¦ÇÑ ÀÌÇØ¸¦ °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù.

µðÁöÅÐ Æä³ëŸÀÌÇÎ ¿ëµµÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ±â¼úÀº ¹«¾ùÀΰ¡?

µðÁöÅÐ Æä³ëŸÀÌÇÎÀº ½º¸¶Æ®ÆùÀÇ ¼¾¼­, ¿þ¾î·¯ºí, ¸Ó½Å·¯´×, Çൿ ºÐ¼® µî ´Ù¾çÇÑ Ã·´Ü ±â¼úÀ» Ȱ¿ëÇϰí ÀÖ½À´Ï´Ù. ÈÞ´ëÆùÀº À¯ºñÄõÅͽº¼º°ú ¼¾¼­°¡ dzºÎÇÑ ¾ÆÅ°ÅØÃ³·Î ÀÎÇØ °¡¼Óµµ°è, ÅëÈ­/¹®ÀÚ ¸ÞŸµ¥ÀÌÅÍ, ¾Û »ç¿ë ÇöȲ, À§Ä¡ Á¤º¸ µîÀÇ ÆÐ½Ãºê µ¥ÀÌÅ͸¦ ¼öÁýÇÏ´Â ÁÖ¿ä Ç÷§ÆûÀ¸·Î ±â´ÉÇÕ´Ï´Ù. ¿þ¾î·¯ºíÀº ½É¹Ú¼ö, ÇǺΠÀüµµµµ, ¼ö¸é Áֱ⠵îÀÇ »ý¸®Àû ½ÅÈ£¸¦ Ç¥ÇöÇü µ¥ÀÌÅͼ¼Æ®¿¡ Ãß°¡ÇÏ¿© ÀÌ·¯ÇÑ ±â´ÉÀ» È®ÀåÇÕ´Ï´Ù.

ÀÌÈÄ ¸Ó½Å·¯´× ¾Ë°í¸®ÁòÀÌ Àû¿ëµÇ¾î Çൿ ÆÐÅÏÀ» µµÃâÇϰí, ±âÁØÄ¡·ÎºÎÅÍÀÇ ÆíÂ÷¸¦ °¨ÁöÇϰí, ÀÓ»óÀû À§Çè »ç°ÇÀ» ¿¹ÃøÇÕ´Ï´Ù. ÀÚ¿¬ ¾ð¾î ó¸®(NLP)´Â °¨Á¤Àû Åæ, ÀÎÁö ±â´É ÀúÇÏ, ½ºÆ®·¹½º ÁöÇ¥¿¡ ´ëÇÑ À½¼º ¹× ÅØ½ºÆ® µ¥ÀÌÅ͸¦ ºÐ¼®ÇÏ´Â µ¥¿¡µµ »ç¿ëµË´Ï´Ù. ¾ÈÀüÇÑ Å¬¶ó¿ìµå Ç÷§Æû°ú ¿§Áö ÄÄÇ»ÆÃ ¸ðµ¨Àº ÇÁ¶óÀ̹ö½Ã °ü¸®°¡ °­È­µÈ ½Ç½Ã°£ ºÐ¼®À» °¡´ÉÇÏ°Ô Çϸç, µ¥ÀÌÅÍ ¾Ïȣȭ ¹× ºñ½Äº°È­ ±â¼úÀº ÁøÈ­ÇÏ´Â µðÁöÅÐ Çコ ÇÁ¶óÀ̹ö½Ã ±ÔÁ¦¸¦ ÁؼöÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù.

ÇコÄÉ¾î ¹× Á¶»ç »ýŰè Àü¹Ý¿¡¼­ ¾î¶² ÀÌ¿ë »ç·Ê°¡ äÅÃÀ» ÃËÁøÇϰí Àִ°¡?

µðÁöÅÐ Æä³ëŸÀÌÇÎÀº ¿ì¿ïÁõ, ºÒ¾ÈÀå¾Ö, ¾ç±Ø¼º Àå¾Ö, Á¶Çöº´, Á¤½ÅºÐ¿­Áõ, PTSD¿Í °°Àº »óŸ¦ ¸ð´ÏÅ͸µÇÏ´Â µ¥ »ç¿ëµÇ´Â Á¤½ÅÀÇÇÐ ¹× ÇൿÀÇÇп¡¼­ °­·ÂÇÑ Ã¤ÅÃÀÌ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù. ÀÓ»óÀǵéÀº ¼öµ¿Àû µ¥ÀÌÅ͸¦ »ç¿ëÇÏ¿© ±âºÐ º¯È­¸¦ °¨ÁöÇϰí, Àç¹ßÀÇ Á¶±â °æ°í ½ÅÈ£¸¦ ½Äº°Çϰí, Ä¡·áÀÇ °³º°È­¸¦ °³¼±Çϱâ À§ÇØ ¼öµ¿Àû µ¥ÀÌÅ͸¦ »ç¿ëÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¾ËÃ÷ÇÏÀ̸Ӻ´, ÆÄŲ½¼º´°ú °°Àº ½Å°æ ÅðÇ༺ ÁúȯÀÇ ±â¾ï·Â, ÁÖÀÇ·Â, ½ÇÇà ±â´ÉÀ» ÃßÀûÇϱâ À§ÇØ ÀÎÁö ±â´É ÇコÄɾµµ Ȱ¿ëµÇ°í ÀÖ½À´Ï´Ù.

¸¸¼ºÁúȯ °ü¸®¿¡¼­ µðÁöÅÐ Æä³ëŸÀÌÇÎÀº ´ç´¢º´, ½ÉÇ÷°ü Áúȯ, ºñ¸¸ µîÀÇ Áõ»ó¿¡¼­ »ýȰ½À°ü Çൿ, Ä¡·á ¼øÀÀµµ, »ý¸®Àû ¹ÝÀÀÀ» ¸ð´ÏÅ͸µÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. Çмú¿¬±¸ ±â°ü°ú Á¦¾à ¿¬±¸ ±â°üÀº Á¾´Ü ¿¬±¸, ½ÇÁ¦ Áõ°Å »ý¼º, µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿ °³¹ß¿¡ µðÁöÅÐ Æä³ëŸÀÌÇÎÀ» Ȱ¿ëÇϰí ÀÖ½À´Ï´Ù. û¼Ò³â °Ç°­, ÀÓ»êºÎ °Ç°­, Áßµ¶ ȸº¹, µðÁöÅÐ Ä¡·áÁ¦¿Í °°Àº »õ·Î¿î ¿ëµµ´Â ƯÈ÷ ¿ø°ÝÁö³ª ¼Ò¿ÜµÈ Áö¿ª¿¡¼­ ±× ¹üÀ§¸¦ ´õ¿í È®ÀåÇϰí ÀÖ½À´Ï´Ù.

µðÁöÅÐ Æä³ëŸÀÌÇÎ ½ÃÀåÀÇ ±Þ¼ºÀå ¿øµ¿·ÂÀº?

µðÁöÅÐ Æä³ëŸÀÌÇÎ ½ÃÀåÀÇ ¼ºÀåÀº ¸ð¹ÙÀÏ Çコ ±â¼úÀÇ ÀÓ»ó Áø·á¿¡ ´ëÇÑ ÅëÇÕ È®´ë, Áö¼ÓÀû ÀÌ°í °³ÀÎÈ­µÈ °Ç°­ ¸ð´ÏÅ͸µ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, Çൿ ºÐ¼® ¹× µðÁöÅÐ Á¤½Å°Ç°­ Ç÷§Æû¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡ µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ¿Í ¿¬±¸ÀÚµéÀº ƯÈ÷ Á¤½ÅÀÇÇÐ ¹× ¿¹¹æÀÇÇÐ ºÐ¾ß¿¡¼­ µðÁöÅÐ Æä³ëŸÀÌÇÎÀ» Ȱ¿ëÇÏ¿© ±âÁ¸ÀÇ ¿¡ÇÇ¼Òµå ±â¹Ý Ä¡·á ¸ðµ¨ÀÌ ³²±ä °£±ØÀ» ¸Þ¿ì±â À§ÇØ µðÁöÅÐ Æä³ëŸÀÌÇÎÀ» Ȱ¿ëÇϰí ÀÖ½À´Ï´Ù.

Á¤½Å°Ç°­¿¡ ´ëÇÑ Àü ¼¼°èÀûÀÎ ÀÎ½Ä Áõ°¡, ¿þ¾î·¯ºí ¹ÙÀÌ¿À¼¾¼­ÀÇ º¸±Þ, °á°ú ±â¹Ý Ä¡·á·ÎÀÇ Àüȯ, È®Àå °¡´ÉÇÑ ¿ø°Ý ¸ð´ÏÅ͸µ ÅøÀÇ Çʿ伺°ú °°Àº ÃÖÁ¾ ¿ëµµ µ¿ÇâÀÌ µµÀÔ¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. µðÁöÅÐ Ä¡·áÁ¦¿Í ȯÀÚ Âü¿©Çü Ç÷§ÆûÀÇ µîÀåµµ ÅëÇÕÇü Ç¥ÇöÇü Åø¿¡ ´ëÇÑ ¼ö¿ä¸¦ ºÒ·¯ÀÏÀ¸Å°°í ÀÖ½À´Ï´Ù. µðÁöÅÐ Çコ »ýŰ谡 ¼º¼÷ÇÏ°í ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©°¡ ¼öµ¿Àû °Ç°­ ¸ð´ÏÅ͸µÀ» Áö¿øÇÏ´Â ¹æÇâÀ¸·Î ÁøÈ­ÇÔ¿¡ µû¶ó µðÁöÅÐ Æä³ëŸÀÌÇÎÀº µ¥ÀÌÅͺ£À̽ºÀÇ ´Éµ¿Àû °Ç°­°ü¸® Á¦°øÀÇ ±â¹ÝÀÌ µÉ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

ºÎ¹®

µ¥ÀÌÅÍ ½ºÆ®¸²(¾×Ƽºê µ¥ÀÌÅÍ ½ºÆ®¸², ÆÐ½Ãºê µ¥ÀÌÅÍ ½ºÆ®¸²), µð¹ÙÀ̽º À¯Çü(½º¸¶Æ®Æù µð¹ÙÀ̽º, ¿þ¾î·¯ºí ÀÇ·á µð¹ÙÀ̽º, ±âŸ µð¹ÙÀ̽º), ¾ÖÇø®ÄÉÀ̼Ç(±âºÐ Àå¾Ö ¾ÖÇø®ÄÉÀ̼Ç, Á¶¿ïÁõ ¾ÖÇø®ÄÉÀ̼Ç, ¿ÀÇÇ¿ÀÀÌµå °úÀ× ¼·Ãë ŽÁö ¾ÖÇø®ÄÉÀ̼Ç, À¯ÇØ À½ÁÖ Çൿ ¾ÖÇø®ÄÉÀ̼Ç, ±âŸ ¾ÖÇø®ÄÉÀ̼Ç)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹(ÁÖ¸ñ 42»ç)

AI ÅëÇÕ

¿ì¸®´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI Åø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾ç ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÔ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Digital Phenotyping Market to Reach US$2.6 Billion by 2030

The global market for Digital Phenotyping estimated at US$1.6 Billion in the year 2024, is expected to reach US$2.6 Billion by 2030, growing at a CAGR of 8.6% over the analysis period 2024-2030. Active Data Stream, one of the segments analyzed in the report, is expected to record a 9.9% CAGR and reach US$1.9 Billion by the end of the analysis period. Growth in the Passive Data Stream segment is estimated at 5.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$429.2 Million While China is Forecast to Grow at 13.7% CAGR

The Digital Phenotyping market in the U.S. is estimated at US$429.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$570.6 Million by the year 2030 trailing a CAGR of 13.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.3% and 8.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.8% CAGR.

Global Digital Phenotyping Market - Key Trends & Drivers Summarized

What Is Digital Phenotyping and Why Is It Gaining Attention in Health Monitoring?

Digital phenotyping refers to the real-time collection and analysis of data from personal digital devices-such as smartphones and wearables-to assess behavioral and physiological patterns that relate to an individual's mental or physical health. By passively monitoring variables such as movement, speech, typing patterns, sleep cycles, social interactions, and GPS data, digital phenotyping generates a dynamic and continuous profile of an individual’s health state. This data-driven approach enables early detection of anomalies, personalized interventions, and longitudinal tracking, especially in mental health, neurology, and chronic disease management.

The increasing prevalence of mental health conditions, coupled with a global push toward personalized and preventive care, is positioning digital phenotyping as a breakthrough solution in digital health. It shifts the paradigm from episodic, clinic-based assessments to continuous, ecological monitoring-providing clinicians with deeper, contextual insights into patients’ real-world behavior. In research, it opens new pathways to understand correlations between digital behavior and psychiatric or neurological outcomes, enabling a more nuanced understanding of human health.

Which Technologies Are Empowering the Growth of Digital Phenotyping Applications?

Digital phenotyping leverages a range of advanced technologies including smartphone sensors, wearables, machine learning, and behavioral analytics. Mobile phones serve as the primary platform due to their ubiquity and sensor-rich architecture, capturing passive data such as accelerometry, call/text metadata, app usage, and geolocation. Wearables extend these capabilities by adding physiological signals like heart rate, skin conductance, and sleep cycles into the phenotypic dataset.

Machine learning algorithms are then applied to derive behavioral patterns, detect deviations from baseline norms, and predict clinical risk events. Natural language processing (NLP) is also used to analyze speech and text data for emotional tone, cognitive decline, or stress indicators. Secure cloud platforms and edge computing models are enabling real-time analytics with enhanced privacy controls, while data encryption and de-identification techniques help ensure compliance with evolving digital health privacy regulations.

Which Use Cases Are Driving Adoption Across Healthcare and Research Ecosystems?

Digital phenotyping is gaining strong adoption in psychiatry and behavioral health, where it is being used to monitor conditions such as depression, anxiety, bipolar disorder, schizophrenia, and PTSD. Clinicians are using passive data to detect mood changes, identify early warning signs of relapse, and improve treatment personalization. It is also being used in cognitive health to track memory, attention, and executive function in neurodegenerative conditions such as Alzheimer’s disease and Parkinson’s disease.

In chronic disease management, digital phenotyping helps monitor lifestyle behaviors, treatment adherence, and physiological response in conditions like diabetes, cardiovascular disease, and obesity. Academic and pharmaceutical research organizations are leveraging digital phenotyping in longitudinal studies, real-world evidence generation, and digital biomarker development. Emerging applications in adolescent health, maternal wellness, addiction recovery, and digital therapeutics are expanding the scope further, particularly in remote and underserved populations.

What Is Driving the Rapid Expansion of the Digital Phenotyping Market?

The growth in the digital phenotyping market is driven by several factors, including the expanding integration of mobile health technologies into clinical care, growing demand for continuous and personalized health monitoring, and rising investments in behavioral analytics and digital mental health platforms. Healthcare providers and researchers are increasingly turning to digital phenotyping to fill the gaps left by traditional episodic care models, especially in psychiatry and preventive medicine.

End-use trends such as the global rise in mental health awareness, the proliferation of wearable biosensors, the shift toward outcome-based care, and the need for scalable remote monitoring tools are fueling adoption. The emergence of digital therapeutics and patient engagement platforms is also catalyzing demand for integrated phenotyping tools. As digital health ecosystems mature and regulatory frameworks evolve to support passive health monitoring, digital phenotyping is set to become a foundational element in data-driven, proactive healthcare delivery.

SCOPE OF STUDY:

The report analyzes the Digital Phenotyping market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Data Stream (Active Data Stream, Passive Data Stream); Device Type (Smartphone Devices, Wearable Medical Devices, Other Devices); Application (Mood Disorders Application, Bipolar Disorder Application, Opioid Overdose Detection Application, Harmful Alcohol Drinking Behavior Application, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â